Evonik's Standalone Case Rests on a Single Number: 2027 EBITDA
Published on 11/20/2026 at 22:31 | Editorial boerse-global.deThe bid is gone, but the arithmetic that matters hasn't changed. Evonik now trades at 18.17 euros, down from a 52-week high of 22.52 euros reached on 18 November and a close of 18.30 euros yesterday — a slide that followed BASF's decision to walk away from a takeover attempt. Yet the price gap to the abandoned offer tells investors almost nothing about whether the chemicals maker is cheap. What does is the operating earnings forecast for 2027.
BASF ended its pursuit yesterday after Evonik turned down two non-binding all-cash proposals, the last pitched at 24 euros a share. The suitor departed with a parting shot: Evonik's prospects as a standalone company, and the risks attached, did not justify a higher valuation in BASF's view. It never put a figure on those risks. Nor does the 24-euro offer serve as a floor for the standalone valuation — it belonged to a transaction BASF has chosen not to pursue.
Jefferies trims the yardstick
On 11 November, Jefferies cut its 2027 EBITDA forecast by 9%, citing fading tailwinds from supply disruptions in the Middle East and rising costs. In the same reassessment the broker downgraded Evonik from "Buy" to "Hold" while lifting its price target to 21 euros from 20. The higher target, in other words, did not rest on improved operating expectations — a distinction worth keeping in mind.
That leaves the reduced earnings estimate as the more telling signal for anyone weighing the standalone business. It gives shareholders a concrete test: can operating performance hold up well enough to head off further downward revisions?
A 40% quarterly jump, built largely on prices
The third-quarter figures show real momentum. Adjusted EBITDA from continuing operations came in at around 630 million euros, up roughly 40% from just under 450 million a year earlier. Evonik has also sharpened its full-year guidance: adjusted EBITDA for 2026 should land in the upper half of the 2.0 to 2.2 billion euro range, against just under 1.9 billion euros in 2025. Even the midpoint of 2.1 billion euros would sit about 12% above the prior year.
Should investors sell immediately? Or is it worth buying Evonik?
The bottom line was less flattering. The quarter closed with a loss of 53 million euros, narrower than the 106 million euro deficit a year before, after Evonik booked a structural charge of just over 310 million euros tied to the expansion of its restructuring programme — roughly half the adjusted EBITDA generated in the same three months.
Management attributes the earnings leap mainly to pricing, and expects that tailwind to fade. Profit driven by higher prices can erode faster than gains from volume or permanently lower costs, and a single strong quarter cannot show how much of the increase survives once pricing stops helping.
The second restructuring phase is still on the drawing board
The overhaul itself is not yet fully mapped out. Under phase two of the programme, some 3,200 jobs are to go worldwide between 2027 and 2029, including about 2,150 in Germany. Evonik is still working up the detailed measures, and intends to have them finalised by the end of 2026 — the first real gauge of how far implementation preparations have progressed.
ODDO BHF moved in the opposite direction to Jefferies on the ratings front, downgrading Evonik to "Neutral" today and cutting its target to 19 euros from 22, pointing to the collapse of the BASF approach. The question for investors, the firm's move implies, is whether Evonik earns enough on its own to justify a richer multiple.
Ownership overhang and union pressure
Two further variables bear watching. The IG BCE union criticised the RAG-Stiftung's dividend policy today, according to Handelsblatt, and demanded fresh commitments on investment, employment, training and sites. The foundation, for its part, is sticking to its goal of reducing its Evonik stake step by step from around 43% to 25.1%, Reuters reported. Neither the union's demands nor the stake target are completed measures; what counts for valuation is whether decisions follow that alter Evonik's financial room to manoeuvre.
Management told employees on Wednesday, per Reuters, that it remains convinced of Evonik's future as an independent company. That is a statement of intent, not an earnings forecast. The cheaper scenario would require Evonik to demonstrate operationally that it can absorb the fading tailwind and rising costs better than feared — and then a more favourable reading of the business would be possible even without a takeover.
Evonik at a turning point? This analysis reveals what investors need to know now.
The next revision is the real test
Should the pressures Jefferies identified persist or intensify, estimates could fall further. In that case even a price well below the old offer would prove nothing about value: the discount would merely measure how far the market has drifted from the bid, not whether the stock is cheap against future earnings.
Absent further cuts to operating forecasts, a stabilisation of the shares is plausible without any renewed takeover speculation. If estimates roll over again, the case for a self-powered re-rating loses substance — even if the price bounces in the meantime. The next hard checkpoint is therefore an update to the 2027 EBITDA estimate, which will show whether the burdens Jefferies flagged are already fully reflected or whether investors should brace for weaker operating results. An unchanged or higher figure would support the brighter scenario; another reduction would signal that the lower price alone does not clear the earnings risk.
Evonik reports full-year 2026 results on 4 March 2027. At least 2.1 billion euros of adjusted EBITDA would confirm the operating strength — though it would say nothing yet about the long-term success of the restructuring.
Ad
Evonik Stock: New Analysis - 20 November
Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
